Effect of Iboga Alkaloids on µ-Opioid Receptor-Coupled G Protein Activation

Antonio, Tamara, Childers, Steven R., Rothman, Richard B., Dersch, Christina M., King, Christine, Kuehne, Martin, Bornmann, William G., Eshleman, Amy J., Janowsky, Aaron, Simon, Eric R., Reith, Maarten E. A., Alper, Kenneth · 2013 · PLoS ONE

AI-extracted · unverified · confirm at source

CRITICAL MECHANISM FINDING: Ibogaine, noribogaine, 18-MC are MOR ANTAGONISTS (Ki 3-13µM), NOT agonists. Opioid withdrawal attenuation cannot be explained by MOR agonism - novel mechanism required.

Dosing: N/A (functional Ki 3–13 µM for MOR) (not-specified)